Latanoprost for glaucoma: primum non nocere – Authors' reply

There is no single measure to identify glaucoma-related disability and the best visual field metric of glaucoma damage to relate disease severity to disability remains unclear.2 However, the small amount of visual field loss triggering a trial endpoint was probably not sufficient to affect a partici...

Full description

Saved in:

Bibliographic Details
Published in:	The Lancet (British edition) Vol. 386; no. 9994; p. 652
Main Authors:	Garway-Heath, David F, Bunce, Catey, Broadway, David C, Martin, Keith R, Lascaratos, Gerassimos, Wormald, Richard P
Format:	Journal Article
Language:	English
Published:	England Elsevier Ltd 15-08-2015 Elsevier Limited
Subjects:	Antihypertensive Agents - administration & dosage Drug therapy Drugs Female Glaucoma Glaucoma, Open-Angle - drug therapy Humans Internal Medicine Male Prostaglandins F, Synthetic - administration & dosage Quality of life
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	There is no single measure to identify glaucoma-related disability and the best visual field metric of glaucoma damage to relate disease severity to disability remains unclear.2 However, the small amount of visual field loss triggering a trial endpoint was probably not sufficient to affect a participant's vision-related quality of life.
Bibliography:	SourceType-Other Sources-1 content type line 63 ObjectType-Correspondence-1 ObjectType-Commentary-2
ISSN:	0140-6736 1474-547X
DOI:	10.1016/S0140-6736(15)61500-8